GlobeNewswire Inc.··NaOcular Therapeutix to Release SOL-1 Phase 3 Results for Wet AMD Treatment
Ocular Therapeutix announces Phase 3 results for SOL-1 wet AMD treatment on February 17, 2026. AXPAXLI data presentation follows at Macula Society Annual Meeting.
OCULPhase 3 clinical trialbiopharmaceutical